TaiMed Biologics (TPEX:4147)

Executive Summary

TaiMed Biologics is a Taiwan‐based commercial‐stage biopharmaceutical company focused on infectious diseases and immunology. It markets Trogarzo® (ibalizumab‐uiyk), a first‐in‐class humanized anti‐CD4 monoclonal antibody for multi‐drug resistant HIV‐1, and leverages its CD4‐targeted platform to develop a pipeline of long‐acting dual‐antibody and antibody‐drug conjugate (ADC) therapeutics. Additionally, the company offers contract development and manufacturing services (CDMO) to global partners. Since its founding in 2020, TaiMed has raised approximately $150 million and is publicly traded on the Taipei Exchange (TPEX:4147). With Trogarzo as a revenue‐generating asset and ongoing clinical programs, TaiMed is positioned to address significant unmet needs in HIV therapy. Its proprietary platform enables differentiation through novel mechanisms of action, while the CDMO business provides a stable income stream and strategic partnerships. Key near‐term value drivers include label expansion for Trogarzo, progress on next‐generation HIV candidates, and expansion of its CDMO client base. The company’s ability to navigate regulatory pathways and commercialize globally will be critical to its growth.

Upcoming Catalysts (preview)

• 2027-01-01Trogarzo label expansion for broader HIV patient population50% success
• 2027-06-30Phase 2/3 data readout for long-acting dual-antibody HIV candidate40% success
• 2026-12-31Major CDMO partnership or manufacturing deal60% success